Switch from Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Kidney Transplantation

被引：18

作者：

Iaria, G. ^{[1
]}

Sforza, D. ^{[1
]}

Angelico, R. ^{[1
]}

Toti, L. ^{[1
]}

de Luca, L. ^{[1
]}

Manuelli, M. ^{[1
]}

Bellini, I. ^{[1
]}

Manzia, T. M. ^{[1
]}

Anselmo, A. ^{[1
]}

Tisone, G. ^{[1
]}

机构：

[1] Tor Vergata Univ, Transplant Unit, S Eugenio Hosp, Rome, Italy

来源：

TRANSPLANTATION PROCEEDINGS | 2011年 / 43卷 / 04期

关键词：

D O I：

10.1016/j.transproceed.2011.01.130

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Advagraf is a new modified-release once-daily formulation of tacrolimus. The aim of this study was to define the efficacy and safety of switching from Prograf to Advagraf immunosuppression in kidney transplant recipients. The switched dose ratio of Prograf to Advagraf was 1:1. Forty-one patients (34 men and 7 women) were switched at 36.6 +/- 16.1 months after kidney transplantation. All patients maintained stable renal function and the conversion. In 16 subjects it was possible to withdraw steroid administration after obtaining adequate Advagraf blood levels, among whom 14 remained steroid free. Adverse events, including dizziness and tinnitus, were reported in 1 patient, who was reverted to Prograf. One patient who was receiving triple therapy with low tacrolimus blood levels experienced are acute rejection episode. The switch to Advagraf was safe and efficacious in kidney transplant recipients with or without steroid administration. Moreover, interruption of steroid was possible and well tolerated after achieving adequate stable blood levels with Advagraf.

引用

页码：1028 / 1029

页数：2

共 8 条

[1] Frequency and impact of nonadherence to immunosuppressants after renal transplantation: A systematic review
Butler, JA
Roderick, P
Mullee, M
Mason, JC
Peveler, RC
[J]. TRANSPLANTATION, 2004, 77 (05) : 769 - 776
[2] Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant Recipients
Comuzzi, C.
Lorenzin, D.
Rossetto, A.
Faraci, M. G.
Nicolini, D.
Garelli, P.
Bresadola, V.
Toniutto, P.
Soardo, G.
Baroni, G. S.
Adani, G. L.
Risaliti, A.
Baccarani, U.
[J]. TRANSPLANTATION PROCEEDINGS, 2010, 42 (04) : 1320 - 1321
[3] First clinical experience with the new once-daily formulation of tacrolimus
First, M. Roy
[J]. THERAPEUTIC DRUG MONITORING, 2008, 30 (02) : 159 - 166
[4] Gonzalez-Molina M, 2010, NDT PLUS S2, V3, pii32
[5] Kramera BK, 2010, AM J TRANSPLANT, V10, P1
[6] Lebranchu Y, 2009, Transplant Proc, V41, pS39, DOI 10.1016/j.transproceed.2009.06.160
[7] Once Daily Tacrolimus Formulation: Monitoring of Plasma Levels, Graft Function, and Cardiovascular Risk Factors
Mecule, A.
Poli, L.
Nofroni, I.
Bachetoni, A.
Tinti, F.
Umbro, I.
Barile, M.
Berloco, P. B.
Mitterhofer, A. P.
[J]. TRANSPLANTATION PROCEEDINGS, 2010, 42 (04) : 1317 - 1319
[8] Modified Release Tacrolimus in De Novo Immunosuppression After Simultaneous Pancreas-Kidney Transplantation-A First Single-Center Experience
Schenker, P.
Klein, T.
Krueger, B.
Claas, S.
Wunsch, A.
Traska, T.
Kraemer, B. K.
Viebahn, R.
[J]. TRANSPLANTATION PROCEEDINGS, 2009, 41 (06) : 2573 - 2575

← 1 →